Publications in collaboration with researchers from University of Tübingen (38)

2024

  1. Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

    Advances in Therapy, Vol. 41, Núm. 2, pp. 696-715

  2. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, Núm. 3, pp. 194-202

2023

  1. Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT

    Bone Marrow Transplantation, Vol. 58, Núm. 11, pp. 1182-1188

  2. Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma

    Advances in Therapy, Vol. 40, Núm. 5, pp. 2412-2425

  3. Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS

    Blood cancer journal

  4. Enhancing Adaptive Teaching of Reading Skills Using Digital Technologies: The LATILL Project

    Lecture Notes in Educational Technology (Springer Science and Business Media Deutschland GmbH), pp. 1092-1098

  5. Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation

    Haematologica

2022

  1. Doublecortin in the Fish Visual System, a Specific Protein of Maturing Neurons

    Biology, Vol. 11, Núm. 2

  2. Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk

    Prostate Cancer and Prostatic Diseases, Vol. 25, Núm. 2, pp. 274-282

  3. Teclistamab in Relapsed or Refractory Multiple Myeloma

    New England Journal of Medicine, Vol. 387, Núm. 6, pp. 495-505

2021

  1. 1q21.1 distal copy number variants are associated with cerebral and cognitive alterations in humans

    Translational psychiatry, Vol. 11, Núm. 1, pp. 182

  2. Cultures of glial cells from optic nerve of two adult teleost fish: Astatotilapia burtoni and Danio rerio

    Journal of Neuroscience Methods, Vol. 353

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  4. Total body irradiation + fludarabine compared to busulfan + fludarabine as “reduced-toxicity conditioning” for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT

    Bone Marrow Transplantation, Vol. 56, Núm. 2, pp. 481-491

2020

  1. Early M-Protein Dynamics Predicts Progression-Free Survival in Patients With Relapsed/Refractory Multiple Myeloma

    Clinical and Translational Science, Vol. 13, Núm. 6, pp. 1345-1354

2019

  1. Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation

    Haematologica, Vol. 104, Núm. 5, pp. 929-936

  2. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

    The Lancet, Vol. 393, Núm. 10168, pp. 253-264

  3. Sox2 expression in the visual system of two teleost species

    Brain Research, Vol. 1722

2018

  1. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of CASTOR

    Haematologica, Vol. 103, Núm. 12, pp. 2079-2087

  2. Prevention and management of adverse events of novel agents in multiple myeloma: A consensus of the European Myeloma Network

    Leukemia, Vol. 32, Núm. 7, pp. 1542-1560